Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Employer
-
Field
-
microfluidic platform for studying bacterial lung and bladder infections and testing new antibacterial drugs is currently developed. The platform includes a microfluidic system for culturing advanced in-vitro
-
essential for procedural success. Due to challenging imaging conditions, the quality of endoscopic videos can be significantly compromised by a range of artifacts. This project seeks to develop the next
-
disease and to develop pioneering therapies benefiting the lives of patients in areas of unmet need. With more than 70 research groups and 800 employees, the Department of Biomedicine is the largest
-
. We seek individuals who will develop and lead a research program at the forefront of the discipline and who will also be committed to excellence in undergraduate and graduate teaching. Approaches
-
and/or the University of Zurich. Wyss Zurich supports projects focusing on developing treatment protocols and clinical therapies, as well as novel technologies and intelligent systems in the emerging
-
In this role, you will lead projects centered on the design and development of innovative experimental testing systems and their digital counterparts. You will be responsible for the conception
-
expertise on optimizing codes and HPC workloads, conduct scaling analyses by means of performance / profiling tools, identify bottlenecks and develop strategies for optimization. You will inspect codes
-
experience. IOB is a research institute combining basic and clinical research. Its mission is to drive innovations in understanding vision and its diseases and develop new therapies for vision loss. It is a
-
. Dagmar Iber, which uses advanced imaging and computational tools to develop data-driven, mechanistic models of biological systems. Located in Basel, the Department of Biosystems Science and Engineering (D
-
to establish an innovative platform for peptide drug discovery. Project background Peptides are privileged modalities for the development of new therapeutic avenues. To address unexploited targets and offer